Table 4.
Antimicrobial susceptibility profile of Gram-negative bacteria isolated from patients with either peri-ocular or ocular infection at Eye Unit Boru-meda General Hospital, February1to April 30, 2021
| Antimicrobials | Isolated bacterial spp and their AST pattern | |||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Moraxella spps. n = 32 |
H.influnzae, n = 9 | Neisseria gonorrhoeae n = 7 |
P. aeruginosa n = 3 |
E.coli n = 5 |
Acinetobacter species n = 5 |
Shigella species n = 4 |
Total Gram negative n (%) |
|||||||||
| S | R | S | R | S | R | S | R | S | R | S | R | S | R | S | R | |
| P | 13(40.6) | 19(59.4) | ND | ND | 1(14.3) | 6(85.7) | ND | ND | ND | ND | ND | ND | ND | ND | 14(35.9) | 25(64.1) |
| TE | ND | ND | 1(11.1) | 8(88.9) | - | 7(100) | ND | ND | 3(60) | 2 (40) | 2 (40) | 3(60 | 2 (50) | 2 (50) | 11(28.2) | 28(71.8) |
| ERY | ND | ND | ND | ND | ND | ND | ND | ND | 4(80) | 1 (20) | ND | ND | 2 (50) | 2(50) | 7(38.9) | 11(61.1) |
| AZM | ND | ND | 8(88.9) | 1(11.10 | ND | ND | ND | ND | 4(80) | 1 (20) | ND | ND | 2 (50) | 2 (50) | 15(55.6) | 12(44.4) |
| CPR | 32(100) | - | 9(100) | - | 5(71.4) | 2(28.6) | 3(100) | - | 5(100) | - | 4(80) | 1 (20) | 4(100) | - | 68(73.3) | 6(25.7) |
| DOX | ND | ND | 3 (33.3) | 6(66.7) | ND | ND | ND | ND | - | 5(100) | 3(60) | 2 (40) | 2 (50) | 2 (50) | 10(31.3) | 22(68.7) |
| C | ND | ND | 3(33.30 | 6(66.7) | ND | ND | ND | ND | 2 (40) | 3(60) | ND | ND | 2 (50) | 2 (50) | 13 (48) | 14 (52) |
| GEN | 28(87.5) | 4(12.5) | ND | ND | ND | ND | 3(100) | - | 5(100) | - | 5(100) | - | 4(100) | - | 54(93) | 4 (7) |
| COT | ND | ND | 3(33.3) | 6(66.7) | ND | ND | ND | ND | ND | ND | 3(60) | 2 (40) | ND | ND | 6(42.9) | 8(57.1) |
| NAL | ND | ND | ND | ND | ND | ND | ND | ND | 5(100) | - | ND | ND | 4(100) | - | 17(94.4) | 1(5.6) |
| AUG | 31(96.9) | 1(3.1) | 9(100) | - | ND | ND | ND | ND | 5(100) | - | ND | ND | 4(100) | - | 53(89.8) | 6(10.2) |
| AMP | ND | ND | - | 9(100) | ND | ND | ND | ND | - | 5(100) | ND | ND | - | 4(100) | 0 | 27(100) |
| PIF | ND | ND | ND | ND | ND | ND | 2(66.7) | 1(33.3) | 4(80) | 1 (20) | 4(80) | 1 (25) | 3(75) | 1 (25) | 20(76.9) | 6(23.1) |
| TOB | 6(18.8) | 26(81) | ND | ND | ND | ND | - | 3(100) | ND | ND | ND | ND | ND | ND | 6(17.1) | 29(82.9) |
| CTR | ND | ND | 9(100) | - | 6(85.7) | 1(14.3) | 2(66.7) | 1(33.3) | 5(100) | - | ND | ND | 4(100) | - | 30(81.1) | 7(18.9 |
| VAN | 32(100) | - | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | ND | 32(100) | 0 |
NOTE: S-susceptible, R-resistant, P-Penicillin, TE-tetracycline, ERY-erythromycin, AZM-azithromycin, CPR-ciprofloxacin, DOX-doxycycline, C-chloramphenicol, GEN-gentamicin, COT-trimethoprim/sulphamethaxzole, NAL nalidixic acid, AUG-amoxicillin- clavulanate, AMP-ampicillin, PIF-piperacillin, TOB-tobramycin, CTR-ceftriaxone and VAN-vancomycin, ND-Not done, Other spp includes Klebsiella oxytocin (n = 2), Klebsiella ozanae (n = 1), Proteus mirabilus (n = 2), Citrobacter spp (n = 1), Providencia rettegri (n = 1), Morganella morganai (n = 2)